Skip to main content

Table 1 Baseline clinical and demographic characteristics of the study participants

From: Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults

Characteristic

Number (n = 63)

Percentage (%)

Age, Median (IQR)

31 (28, 37)

 

Sex

  

 Female

37

58.7

Male

26

41.3

Baseline CD4 cell count, Median (IQR)

284 (158, 518)

 

Level of education

  

 Primary

33

52.4

 Secondary

26

41.3

 Tertiary

4

6.3

Religion

  

 Christian

49

77.8

 Muslim

14

22.2

Residence

  

 Rural

1

1.6

 Urban

62

98.4

Employment

  

 No

9

14.3

 Yes

54

85.7

Marital status

  

 Single

33

52.4

 Married

30

47.6

Tuberculosis status at baseline

  

 No symptoms

52

82.5

 TB suspect

10

15.9

 TB disease

1

1.6

Baseline blood pressure

  

 Normal BP

52

82.5

 Pre-hypertension

8

12.7

 Hypertension

3

4.8

HIV clinical stage

  

 Stage 1

61

96.8

 Stage 2

1

1.6

 Stage 3

1

1.6

Body Mass Index (BMI)

  

 Underweight (< 18.5)

7

11.1

 Normal (18.5–24.9)

41

65.1

 Overweight (25.0-29.9)

14

22.2

 Obese (≥ 30)

1

1.6

Waist circumference

  

 Normal

44

69.8

 Increased risk of cardiometabolic complications

10

15.9

 Substantially increased risk of cardiometabolic complications

9

14.3

Smoking status

  

 Smoker

6

9.5

 Non-smoker

57

90.5

Physical activity

  

 GPAQ < 600 MET minutes

8

12.7

 GPAQ ≥ 600 MET minutes

55

87.3

Alcohol consumption

  

 No consumption

33

52.4

 Low risk alcohol consumption

19

30.2

 Hazardous alcohol consumption

6

9.5

 Risk of alcohol dependence

5

7.9

24-week viral loads (Proxy baseline VL), n = 62

  

 Virologically suppressed

63

100

Anti-GAD antibody

  

 Negative

63

100

Anti-IA2 antibody status

  

 Negative

61

96.8

 Positive

2

3.2

Laboratory investigations, Median (IQR)

  

 Creatinine (mg/dl)

0.86 (0.77, 0.98)

 

 LDL (mg/dl)

75.2 (53.8, 90.3)

 

 HDL (mg/dl)

29.6 (24.9, 35.8)

 

 Total cholesterol (mg/dl)

130.9 (111.2, 158.7)

 

 Triglycerides (mg/dl)

95.2 (71.3, 124.0)

 
  1. IQR- interquartile range, BP- blood pressure, GPAQ- Global physical activity questionnaire, MET- metabolic equivalent, anti- GAD- anti- glutamic acid decarboxylase, anti- IA2 - anti- Islet cell antigen-2, LDL- low density lipoproteins, HDL- high density lipoproteins.